BZAM Ltd. (CSE: BZAM) (US-OTC: BZAMF) released its financial results for the three months ended March 31, 2023, revealing record quarterly net revenues of CA$24.1 million ($17.7 million), an increase of 40% compared to CA$17.2 million in Q4 2022, and an increase of 127.9% compared to CA$10.6 million in Q1 2022.
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly